Stock Events

Stock Events

MoonLake Immunotherapeutics 

$15.01
270
-$0.18-1.18% Friday 20:00
+$0.03+0.2%Friday 23:30After hours

Statistics

Day High
15.24
Day Low
14.88
52W High
61.99
52W Low
6.24
Volume
1,427,971
Avg. Volume
1,258,082
Mkt Cap
1.28B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.1
-0.94
-0.79
-0.63
Expected EPS
-0.779668
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-227.32MNet Income

Analyst Ratings

34.80Average Price Target
The highest estimate is 50.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MLTX. It's not an investment recommendation.
NVIDIA
23
NVDA
Amazon
19
AMZN
Microsoft
16
MSFT
Alphabet
16
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals competes in the immunology and inflammation treatment space, directly challenging MoonLake's focus on novel therapeutics for autoimmune diseases.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie has a strong portfolio in immunology, including treatments for conditions that MoonLake targets, making it a direct competitor in the autoimmune disease market.
AMGEN
AMGN
Mkt Cap236.38B
Amgen operates in the biotechnology industry focusing on human therapeutics, including treatments for inflammatory diseases, competing with MoonLake's offerings.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is involved in the discovery, development, and commercialization of medicines in areas similar to MoonLake, including inflammatory and immune-mediated diseases.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb offers a range of biopharmaceutical products that target immune system disorders, directly competing with MoonLake's therapeutic areas.
Novartis
NVS
Mkt Cap304.1B
Novartis AG focuses on patented medicines for a range of diseases, including autoimmune and inflammation, making it a competitor in MoonLake's market.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for autoimmune diseases, competing with MoonLake's immunotherapeutic approaches.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a diverse portfolio in biopharmaceuticals, including drugs for inflammatory and autoimmune diseases, positioning it as a competitor to MoonLake.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. is engaged in the development of pharmaceutical products, including for immune-mediated diseases, competing with MoonLake's focus areas.
Rogers
ROG
Mkt Cap2.28B
Roche Holding AG, with its strong focus on biotechnology and medications for autoimmune diseases, competes in the same space as MoonLake, particularly in the development of innovative therapeutics.

About

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Show more...
CEO
Jorge Santos da Silva
Employees
130
Country
Cayman Islands
ISIN
KY61559X1045

Listings

MX
MX
MLTXN.MX
XNAS
US
MLTX
BOATS
BOATS
MLTX.BOATS

0 Comments

Share your thoughts

FAQ

What is MoonLake Immunotherapeutics stock price today?▼
The current price of MLTX is $15.01 USD — it has decreased by -1.18% in the past 24 hours. Watch MoonLake Immunotherapeutics stock price performance more closely on the chart.
What is MoonLake Immunotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange MoonLake Immunotherapeutics stocks are traded under the ticker MLTX.
Is MoonLake Immunotherapeutics stock price growing?▼
MLTX stock has fallen by -0.79% compared to the previous week, the month change is a -17.8% fall, over the last year MoonLake Immunotherapeutics has showed a -75.44% decrease.
What is MoonLake Immunotherapeutics market cap?▼
Today MoonLake Immunotherapeutics has the market capitalization of 1.28B
When is the next MoonLake Immunotherapeutics earnings date?▼
MoonLake Immunotherapeutics is going to release the next earnings report on November 17, 2026.
What were MoonLake Immunotherapeutics earnings last quarter?▼
MLTX earnings for the last quarter are -0.84 USD per share, whereas the estimation was -0.91 USD resulting in a +7.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MoonLake Immunotherapeutics revenue for the last year?▼
MoonLake Immunotherapeutics revenue for the last year amounts to 0 USD.
What is MoonLake Immunotherapeutics net income for the last year?▼
MLTX net income for the last year is -227.32M USD.
How many employees does MoonLake Immunotherapeutics have?▼
As of September 08, 2026, the company has 130 employees.
In which sector is MoonLake Immunotherapeutics located?▼
MoonLake Immunotherapeutics operates in the Health & Wellness sector.
When did MoonLake Immunotherapeutics complete a stock split?▼
MoonLake Immunotherapeutics has not had any recent stock splits.
Where is MoonLake Immunotherapeutics headquartered?▼
MoonLake Immunotherapeutics is headquartered in ZUG, Cayman Islands.